Neonatal Med Search


Neonatal Med > Volume 22(2); 2015 > Article
Neonatal Medicine 2015;22(2):55-60.
DOI:    Published online May 29, 2015.
Clinical Indications for Inhaled Nitric Oxide Therapy in Neonates.
Tae Jung Sung
Department of Pediatrics, Hallym University College of Medicine, Seoul, Korea.
Nitric oxide (NO) is a colorless, odorless gas that acts as a potent pulmonary vasodilator. When administered via inhalation, NO rapidly diffuses across the alveolarcapillary membrane and binds to hemoglobin, and thus has little effect on the systemic circulation. NO was approved by the United States Food and Drug Administration (US FDA) for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in 1999. Neonatal hypoxic respiratory failure may be caused by persistent pulmonary hypertension of the newborn and other diseases such as meconium aspiration syndrome, sepsis, birth asphyxia, and respiratory distress syndrome that contribute to pulmonary arterial hypertension. Inhaled NO is the only approved treatment in term and late preterm (>34 weeks) neonates with hypoxic respiratory failure associated with pulmonary hypertension, and it reduces the need for extracorporeal membrane oxygenation. The present article will review the clinical indications for US FDA-approved inhaled NO therapy according to evidence-based clinical studies.
Key Words: Neonatal hypoxic respiratory failure; Nitric oxide; Persistent pulmonary hypertension of newborn


Browse all articles >

Editorial Office
34, Sajik-ro 8–gil(King’s Gargen 3 Block 1207), Jongno-gu, Seoul 03174, Republic of Korea
Tel: +82-2-730-1993    Fax: +82-2-730-1994    E-mail:                

Copyright © 2023 by The Korean Society of Neonatology.

Developed in M2PI

Close layer
prev next